Laser-based medical systems provider Iridex Corp. has licensed its MicroPulse photocoagulation technology to Quantel Medical for use in clinical ophthalmic lasers. MicroPulse is a tissue-sparing laser technology that provides ophthalmologists with a noninvasive treatment for diseases that threaten eyesight. It works by electronically “chopping” the laser emission into trains of microsecond pulses, enabling physicians to control the effects on target tissues. “There is a significant need in the marketplace for efficient and durable therapies for retinal diseases associated with the growth of diabetes and the aging population,” said Iridex President and CEO Will Moore. Quantel Medical of Clermont, France, is a division of Quantel that manufactures medical devices for the treatment of ocular diseases. For more information, visit: www.iridex.com or www.quantel-medical.com